The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis

Melanoma Research

Volumn 27, Issue 5, 2017, Pages 519-523

  Puri, Akshjot ^a   Homsi, Jade ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Exacerbation; Immune related adverse events; Metastatic melanoma; Pembrolizumab; Rheumatoid arthritis; Safety

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; PEMBROLIZUMAB; PREDNISONE; RHEUMATOID FACTOR; RIVAROXABAN; THYROTROPIN; TOCILIZUMAB; MONOCLONAL ANTIBODY;

AGED; ANKLE; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; CANCER IMMUNOTHERAPY; CARDIOVERSION; CASE REPORT; CEREBELLUM HEMORRHAGE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOGRAPHY; ELBOW; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HAND; HEART FAILURE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; JOINT SWELLING; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHADENOPATHY; MAINTENANCE DRUG DOSE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NECK; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SHOULDER; TREATMENT RESPONSE; FEMALE; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PROCEDURES; SKIN TUMOR;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 85044433170     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000387     Document Type: Article

References (47)

1. Atkins MB, Kunkel L, Sznol M, Risenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6:S11-S14.
2. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691.
3. Weber JS, Dummer R, de Pil V, Lebbé C, Hodi FS. MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675.
4. Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, et al. Ipilimumab administration for advanced melanoma in patients with preexisting hepatitis B or C infection, a mulitcenter, retrospective case series. J Immunother Cancer 2014; 2:8.
5. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast or prostate cancer. Cancer 2014; 120:1290-1314.
6. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633-639.
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
8. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33:1430-1437.
9. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-319.
10. Segal NH, Ou SI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol 2015; 33:15s.
11. El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo W, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33:LBA101.
12. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-562.
13. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
14. Ribas A, Puzanov I, Dummer R, Sahadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16:908-918.
15. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumabrefractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-1117.
16. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
17. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2:234-240.
18. Abdel-Wahab N, Shah M, Suarez- Almazor M. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune diseases: A systematic review of case reports. Arthritis Rheumatol 2016; 68:S1342.
19. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD1 therapy in patients with advanced melanoma and pre-existing autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2016; 28: S1268-S1376.
20. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-2532.
21. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33:2092-2099.
22. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard of care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-622.
23. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113:1581-1588.
24. Davids MS, Kim HT, Bachireddy P, Costello C, Lihuori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375:143-153.
25. Herz S, Höfer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer 2016; 67:66-72.
26. Aslan A, Aras T, Özdemir E. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation. Leuk Lymphoma 2017; 58:754-755.
27. Shad AT, Huo JS, Darcy C, Abu-Ghosh A, Esposito G, Holuba MJ, et al. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report. Pediatr Blood Cancer 2017; 64:26257.
28. Yared JA, Hardy, N, Singh Z, Badros AZ, Kocoglu M, Yanovich S, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51:850-852.
29. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Wecjesser M, et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51:443-445.
30. Villasboas JC, Ansell, SM, Witzig TE. Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 2016; 7:13260-13264.
31. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 2016; 27:1135-1137.
32. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson, EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 2015; 3:22.
33. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother 2015; 38:211.
34. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014; 32:e69-e71.
35. Jose A, Yiannoullou P, Bhutani S, Denley H, Morton M, Picton M, et al. Renal allograft failure after ipilimumab therapy for metastatic melanoma: A case report and review of the literature. Transplant Proc 2016; 48:3137-3141.
36. Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant 2016; 16:2496-2497.
37. Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer 2016; 4:64.
38. Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: A case report. Cancer Immunol Immunother 2017; 66:45-50.
39. Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol 2016; 95:1913-1915.
40. Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S, et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant 2016; 51:1268-1270.
41. Kwong YL. Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol 2016; 95:1191-1192.
42. Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016; 374:896-898.
43. Jeong HY, Lee YJ, Seo SK, Lee SW, Park SJ, Lee JN, et al. Blocking of monocyte- Associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J Leukoc Biol 2008; 83:755-764.
44. Lukens JR, Cruise MW, Lassen MG, Hahn YS. Blockade of PD-1/B7-H1 interaction restores effector CD8 + T cell responses in a hepatitis C virus core murine model. J Immunol 2008; 180:4875-4884.
45. Trautmann L, Janbazian L, Chomont N, Said EA, Gimming S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
46. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
47. Davar D, Wilson M, Pruckner C, Kirkwood JM. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med 2015; 2015:737389.